Good afternoon :)
Place Order
Add to Watchlist

Bafna Pharmaceuticals Ltd

BAFNAPH

Bafna Pharmaceuticals Ltd

BAFNAPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹191 cr, stock is ranked 2,560
Moderate RiskStock is 2.79x as volatile as Nifty
83.503.73% (+3.00)
83.503.73% (+3.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹191 cr, stock is ranked 2,560
Moderate RiskStock is 2.79x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹191 cr, stock is ranked 2,560
Moderate RiskStock is 2.79x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
479.632.37
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 28.79%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.02% to 0.04%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue86.5566.1078.4344.0242.7371.9786.84118.62155.99146.47
Raw Materialssubtract65.9955.0134.1927.0023.2233.5841.7065.9891.58137.98
Power & Fuel Costsubtract2.382.012.122.502.692.953.935.316.73
Employee Costsubtract6.446.627.479.0110.2511.9814.6515.8719.03
Selling & Administrative Expensessubtract3.303.154.073.133.182.676.925.3913.98
Operating & Other expensessubtract4.393.3934.4015.0625.229.748.147.0910.03
Depreciation/Amortizationsubtract4.113.893.653.423.274.485.495.335.005.56
Interest & Other Itemssubtract12.4711.346.812.130.100.740.792.042.292.53
Taxes & Other Itemssubtract-0.34-0.842.181.500.000.000.000.280.00
EPS-6.53-9.90-7.78-8.34-19.374.482.214.793.110.17
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bafna Pharmaceuticals Ltd26.102.37
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare BAFNAPH with any stock or ETF
Compare BAFNAPH with any stock or ETF
BAFNAPH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding88.30%0.00%0.00%0.00%11.70%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

BAFNAPH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2013

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Sep 19, 2013

News & Opinions
Earnings
Bafna Pharmaceuticals standalone net profit rises 5.65% in the September 2024 quarter

Net profit of Bafna Pharmaceuticals rose 5.65% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 2.48 crore during the previous quarter ended September 2023. Sales declined 0.88% to Rs 40.32 crore in the quarter ended September 2024 as against Rs 40.68 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales40.3240.68 -1 OPM %9.429.83 - PBDT4.203.72 13 PBT2.622.48 6 NP2.622.48 6 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to discuss results

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bafna Pharmaceuticals schedules AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to convene AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Bafna Pharmaceuticals reports standalone net loss of Rs 0.72 crore in the June 2024 quarter

Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024 as against net profit of Rs 6.35 crore during the previous quarter ended June 2023. Sales declined 20.64% to Rs 33.29 crore in the quarter ended June 2024 as against Rs 41.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.2941.95 -21 OPM %3.6314.99 - PBDT1.077.56 -86 PBT-0.376.35 PL NP-0.726.35 PL Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Bafna Pharmaceuticals to declare Quarterly Result

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

2 years agoMoneycontrol

Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter

2 years agoBusiness Standard

Bafna Pharma in talks with multinational pharma firms for brand acquisition

3 years agoFree Press Journal

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

3 years agoBusiness Standard